Daré Bioscience to Participate in Two Upcoming Investor Conferences
14 October 2019 - 11:00PM
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health
innovation, today announced that Sabrina Johnson, its President and
Chief Executive Officer, will present at two upcoming investor
conferences:
- The 2019 Bio Investor Forum at the Westin St. Francis in San
Francisco, California, on Tuesday, October 22, 2019, at 2:45 pm
PDT.
- The Dawson James Securities 5th Annual Small Cap Growth
Conference at the Wyndham Grand Hotel in Jupiter, Florida, on
Tuesday, October 29, 2019, at 3:15 pm EDT.
A live webcast of Ms. Johnson’s presentation at the Dawson James
conference will be available on the Investor Relations section of
Daré’s website at http://ir.darebioscience.com. Following the live
broadcast, a replay will be available through November 12,
2019.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company
committed to the advancement of innovative products for women’s
health. The company’s mission is to identify, develop and bring to
market a diverse portfolio of differentiated therapies that expand
treatment options, improve outcomes and facilitate convenience for
women, primarily in the areas of contraception, vaginal health,
sexual health, and fertility.
Daré’s product portfolio includes potential first-in-category
candidates in clinical development: Ovaprene®, a hormone-free,
monthly contraceptive intravaginal ring; Sildenafil Cream, 3.6%, a
novel cream formulation of sildenafil to treat female sexual
arousal disorder utilizing the active ingredient in Viagra®;
DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2%
to treat bacterial vaginosis via a single application; and
DARE-HRT1, a combination bio-identical estradiol and progesterone
intravaginal ring for hormone replacement therapy following
menopause. To learn more about Daré’s full portfolio of women’s
health product candidates, and mission to deliver differentiated
therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances,
product candidates, clinical trials and other matters using its
investor relations website (http://ir.darebioscience.com), SEC
filings, press releases, public conference calls and webcasts. Daré
uses these channels to communicate with its investors and the
public about the company and other company-related matters. The
information Daré posts on its investor relations website may be
deemed to be material information. Daré encourages investors, the
media, and others interested in the company to review the
information Daré posts on its investor relations website:
www.darebioscience.com.
Contacts:Investors on behalf of Daré
Bioscience, Inc.:Lee RothBurns
McClellanlroth@burnsmc.com212.213.0006
OR
Media on behalf of Daré Bioscience, Inc.:Jake RobisonCanale
Communicationsjake@canalecomm.com619.849.5383
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2024 to May 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From May 2023 to May 2024